Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors

Core Insights - Abeona Therapeutics Inc. has appointed Bernhardt G. Zeiher, MD, FCCP, FACP, and Eric Crombez, MD as new independent members of its Board of Directors, enhancing its leadership team during a critical period for the company [1][2] Group 1: Board Appointments - Dr. Zeiher has over 20 years of drug development experience and has overseen the approval of 15 new treatments for serious diseases with limited treatment options [1][2] - Dr. Crombez is currently the Chief Medical Officer at Ultragenyx Pharmaceutical Inc. and has extensive expertise in clinical development for rare genetic disorders [1][3] Group 2: Leadership Background - Dr. Zeiher previously held multiple roles at Astellas Pharma, culminating in his position as Chief Medical Officer, where he led drug development and regulatory affairs [2] - Dr. Crombez has a background in academia as an assistant professor at UCLA and has led clinical development efforts for gene therapy programs at Dimension Therapeutics [3] Group 3: Company Overview - Abeona Therapeutics is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases, including its investigational therapy pz-cel for recessive dystrophic epidermolysis bullosa [4] - The company operates a fully integrated cGMP manufacturing facility capable of supporting commercial production of pz-cel upon FDA approval [4]